Forest reports solid 3Q, but is pipeline sufficient for patent cliff?
This article was originally published in Scrip
Executive Summary
Forest Laboratories has reported solid third quarter results. But while the firm's current top line is strong, there continues to be concern on the strength of its product portfolio to cushion the blow from the imminent expiry of patents on two of its largest products, SSRI antidepressant Lexapro (escitalopram) and Alzheimer's drug Namenda (memantine HCl).